Broad Institute

MAY 9, 2024

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed. “We

Clinical Trials 52

Clinical Trials Clinical Development Disease Science 52

Vial

MARCH 1, 2024

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. ’s services include supporting life sciences research, analytical solutions, and diagnostics or developing and manufacturing therapeutic interventions.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

The Pharma Data

JANUARY 20, 2021

CytomX expects to use the net proceeds from this offering to further develop its proprietary Probody ® therapeutics pipeline and research. CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues.

Clinical Development 40

Clinical Development Therapies Science Drugs 40

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. Automation. Screening acts as the bedrock of many drug discovery activities. Collaborations.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

OCTOBER 9, 2021

Bristol Myers Squibb continues to expect greater than $4 billion non-risk adjusted revenue target for deucravacitinib in 2029. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib.

Immune Response 52

Immune Response Science Trials Disease 52

The Pharma Data

JANUARY 25, 2021

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Marketing 52

Marketing Disease Clinical Trials Production 52